单用他克莫司和联合五酯胶囊治疗免疫性肾小球疾病的单中心回顾性研究

摘要

Comparing tacrolimus combined wuzhi capsules and tacrolimus therapy autoimmune glomerular disease the efficacy, safety, drug-economics.Retrospectively analyzed autoimmune glomerular disease with a large number of proteinuria which is confirmed by renal biopsy between January 2011 and December 2015 of in the nephrology department of the First Affiliated Hospital of Dalian Medical University, sixty patients were involved, which is divided into two groups: a group of tacrolimus alone and a group of tacrolimus combined Wuzhi capsules.Primary evaluation index is cumulative response rate.Secondary evaluation index is drug side effects and drug-economics.In the 3 months and 6 months follow up, there is statistical difference in amount of the remission between tacrolimus group and tacrolimus combined wuzhi capsules group (P<0.05).The side effects of two groups have no statistical differences (P>0.05), and drug-economics have statistical differences (P<0.05).Tacrolimus combined wuzhi capsule can effectively treat autoimmune glomerular diseases and have a good drug-economics.%对单用他克莫司和联合五酯胶囊治疗免疫性肾小球疾病疗效、安全性和药物-经济效益进行比较.回顾性分析大连医科大学附属第一医院2011年1月~2015年12月行肾活检证实为免疫性肾小球疾病并伴大量蛋白尿的患者60例,分为单用他克莫司组和联合五酯胶囊组.主要评价指标:蛋白尿缓解率、各个时间点蛋白尿缓解率等;次要评价指标:药物副作用、治疗费用及药物-经济学效益.随访第3个月、6个月,他克莫司联合五酯胶囊组蛋白尿缓解人数高于单用他克莫司组(P<0.05),两组副作用无差异(P<0.05),而治疗费用及成本-疗效比有统计学差异(P<0.05);他克莫司联合五酯胶囊可有效降低免疫性肾小球疾病蛋白尿,且具有较好药物经济学效益.